DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
BOTHELL, Wash., May 10, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2017 Health Care Conference at 10:40 a.m. PT (1:40 p.m. ET) on Wednesday, May 17, 2017 in Las Vegas, NV. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
Link: http://www.veracast.com/webcasts/baml/healthcare2017/id46205172515.cfm
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contact: David Schull Russo Partners, LLC (212) 845-4271 [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected]
